EverGlade Insights Archives - EverGlade Consulting

EverGlade Insights

ACTR Initiative clinical trials

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative

ARPA-H launches groundbreaking funding opportunity The Advancing Clinical Trial Readiness (ACTR) Initiative, spearheaded by ARPA-H’s Resilient Systems Office (RSO), aims to revolutionize clinical trials by developing a decentralized, efficient, and accessible infrastructure. Overview of Solicitation The ACTR Initiative is focused on creating tools, networks, and infrastructure to enable decentralized and on-demand clinical trials. By integrating […]

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative Read More »

ARPA-H health equity, technology, and biomedical research

Emerging Health Innovators (EHI) Initiative Proposer’s Day

ARPA-H-SN-25-119 (1) The Advanced Research Projects Agency for Health (ARPA-H) has launched the Emerging Health Innovators (EHI) Initiative, a transformative funding opportunity aimed at empowering early-career researchers and community-based innovators to revolutionize healthcare. To support this initiative, ARPA-H is holding a virtual Proposer’s Day on January 8th, 2025, from 11AM to 4PM EDT. Overview of

Emerging Health Innovators (EHI) Initiative Proposer’s Day Read More »

medical countermeasures for biodefense and infectious diseases

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease

HHS-NIH-NIAID-BAA2025-1 The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has released the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1. This announcement presents an exciting opportunity for researchers, organizations, and industry leaders to contribute to critical biomedical and biodefense initiatives.

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease Read More »

the Joint Biological Tactical Detection System

Joint Biological Tactical Detection System Full Rate Production Request for Information

JBTDS_FRP_RFI_4_Nov_2024_ The U.S. Army’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) recently issued a Request for Information (RFI) regarding Full Rate Production (FRP) of the Joint Biological Tactical Detection System (JBTDS). This RFI aims to collect information on industry capability to produce JBTDS devices which will be used by joint

Joint Biological Tactical Detection System Full Rate Production Request for Information Read More »

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in

Assay Expansion for Chemical Diagnostic System Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

anti-microbial

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials

HHS+DPA+T3+RFI_Antimicrobials+-+Clean+copy+11-7-24+(002) The U.S. Department of Health and Human Services (HHS) Defense Production Act (DPA) Title III Program recently issued a Request for Information (RFI) aimed at strengthening the domestic production of anti-microbial products. This initiative seeks input from industry to assess current capacities and capabilities in producing essential anti-microbials critical for public health and national

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials Read More »

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

pathophysiology lymphatic system and diseases

Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE)

GLIDE_ISO_ARPA-H-SOL-24-111_Final_29_OCT_2024 Program Overview An estimated 10 million Americans are impacted by primary lymphatic diseases, and lymphatic dysfunction contributes to the pathophysiology of many widespread chronic illnesses. Despite the importance of the lymphatic system in disease, there are currently zero FDA-approved treatments, medical devices, or therapies specifically targeting lymphatic growth and function. To catalyze a future

Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Read More »

EverGlade Consulting

EverGlade Consulting Continues Growth with Addition of Nathan Clark

EverGlade Consulting, is pleased to announce the appointment of Nathan Clark as Director, effective November 2024. Mr. Clark brings an extensive background in government contracting and federal funding management, making him a valuable addition to the EverGlade team. Nathan Clark joins EverGlade Consulting with an impressive portfolio, having recently served as the BARDA portfolio leader

EverGlade Consulting Continues Growth with Addition of Nathan Clark Read More »

MTEC RPP military medical needs

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals

MTEC-FY-2025-Multi-Topic-Pre-Announcement Overview of Solicitation The Medical Technology Enterprise Consortium (MTEC) has released an exciting pre-announcement for its 2025 Multi-Topic Request for Proposals (RPP). This RPP calls for innovative medical prototypes addressing a range of focus areas critical to supporting military operations and improving healthcare delivery in challenging environments. Here’s an overview of what to expect

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals Read More »

Scroll to Top
Flask with blue light

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.